Back to Results
Geographic Atrophy Biomarker Evaluation Study (GABiE)
Title |
A biomarker evaluation study in patients with geographic atrophy secondary to age-related macular degeneration (AMD) evaluating the use of microperimetry (fundus-controlled perimetry) and Swept Source-OCT in assessing changes in retinal sensitivity and anatomy over time. |
Therapeutic Area |
Macular Degeneration
|
Principal Investigator |
Shilpa Desai, MD |
Min Age |
60 Years |
Gender |
All |
Contact |
Michael Dixon 617-636-1051
mdixon3@tuftsmedicalcenter.org
|
This study is being done to see if some eye tests could be useful in finding the natural changes that happen over time in the retina (the back part of the eye) of patients with GA secondary to AMD.
Inclusion Criteria
- 20/63 or better approximate Snellen equivalent
- Geographic atrophy (GA) secondary to AMD with no evidence of prior or active choroidal neovascularization
- Ability to perform quality fundus imaging based on ocular measures
Exclusion Criteria
- GA in either eye due to causes other than AMD
- Receiving treatment using investigational drugs for GA/dry AMD
Study Requirements
5 study visits total over I year; imaging at all visits, Visual Acuity testing, 1 optional blood collection, research questionnaires at 3 visits